NCT05718895 2026-04-15
CLINCH
Antengene Corporation
Phase 1 Recruiting
Clinical Trials
12 trialsNCT07141706 2026-04-09
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1 Recruiting
NCT07480681 2026-03-18
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT07473726 2026-03-16
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT04501276 2026-01-08
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Adagene Inc
Phase 1 Completed
NCT05614258 2026-01-08
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
Adagene Inc
Phase 1 Active not recruiting
NCT05394168 2024-04-01
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05277402 2024-02-26
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Adagene Inc
Phase 1 Completed
NCT02665416 2020-04-07
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02444793 2019-02-27
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT01092052 2012-09-07
Study of NMS-1116354 in Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences
Phase 1 Terminated
NCT00996255 2009-10-16
Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences
Phase 1 Terminated